IMR Press / EJGO / Volume 40 / Issue 5 / DOI: 10.12892/ejgo4631.2019
Open Access Review
A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer
Show Less
1 Multidisciplinary Breast Clinic Antwerpen, Antwerp University Hospital - University of Antwerp, Edegem, Belgium
Eur. J. Gynaecol. Oncol. 2019 , 40(5), 714–721; https://doi.org/10.12892/ejgo4631.2019
Published: 10 October 2019
Abstract

Background: The sentinel lymph node biopsy (SLNB) is the standard procedure to assess the lymph node status in women with early stage breast cancer. It is uncertain whether SLNB is useful after neo-adjuvant chemotherapy (NACT) given to women with locally advanced breast cancer. Materials and Methods: A literature search was conducted over a timeframe of 22 years (1994-2016). Forty-three studies evaluating the feasibility and accuracy of SLNB after NACT were identified. Results: The pooled identification rate was 88% and the pooled false negative ratio was 12%. Conclusion: SLNB could be considered as a standard procedure after NACT.

Keywords
Breast cancer
Neo-adjuvant chemotherapy
Sentinel lymph node biopsy
Axillary clearance
Morbidity
SLN
Survival
Figures
Figure 1.
Share
Back to top